Piper Jaffray Companies set a $208.00 price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report published on Wednesday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

A number of other research analysts have also issued reports on the company. Cantor Fitzgerald reaffirmed a buy rating and set a $201.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday. BidaskClub lowered Jazz Pharmaceuticals from a sell rating to a strong sell rating in a report on Wednesday, September 19th. Wells Fargo & Co reaffirmed a buy rating and set a $195.00 target price (up from $182.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, August 15th. Morgan Stanley lowered Jazz Pharmaceuticals from an overweight rating to an equal weight rating and set a $183.00 target price on the stock. in a report on Wednesday, July 11th. Finally, Zacks Investment Research lowered Jazz Pharmaceuticals from a hold rating to a sell rating in a report on Monday, July 16th. Three analysts have rated the stock with a sell rating, three have given a hold rating and fifteen have issued a buy rating to the company’s stock. Jazz Pharmaceuticals currently has an average rating of Buy and a consensus target price of $190.61.

Shares of JAZZ traded up $1.78 during trading hours on Wednesday, reaching $142.19. 1,743,725 shares of the company’s stock traded hands, compared to its average volume of 498,591. The firm has a market capitalization of $9.93 billion, a price-to-earnings ratio of 14.87, a price-to-earnings-growth ratio of 0.89 and a beta of 1.06. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.62 and a current ratio of 3.76. Jazz Pharmaceuticals has a twelve month low of $130.15 and a twelve month high of $184.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, beating analysts’ consensus estimates of $3.32 by $0.26. The company had revenue of $469.37 million for the quarter, compared to analyst estimates of $482.64 million. Jazz Pharmaceuticals had a return on equity of 25.44% and a net margin of 28.09%. The company’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period last year, the company earned $3.22 earnings per share. Analysts forecast that Jazz Pharmaceuticals will post 11.71 EPS for the current fiscal year.

In related news, SVP Paul Treacy sold 1,309 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $176.61, for a total value of $231,182.49. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $175.70, for a total value of $35,140.00. Following the completion of the transaction, the executive vice president now directly owns 25,572 shares in the company, valued at approximately $4,493,000.40. The disclosure for this sale can be found here. Insiders sold a total of 34,678 shares of company stock worth $5,959,173 in the last three months. 3.90% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Stratos Wealth Partners LTD. purchased a new position in Jazz Pharmaceuticals in the 3rd quarter worth about $106,000. Tiverton Asset Management LLC purchased a new position in Jazz Pharmaceuticals in the 2nd quarter worth about $198,000. Moloney Securities Asset Management LLC purchased a new position in Jazz Pharmaceuticals in the 2nd quarter worth about $204,000. FDx Advisors Inc. purchased a new position in Jazz Pharmaceuticals in the 2nd quarter worth about $244,000. Finally, Cadence Capital Management LLC purchased a new position in Jazz Pharmaceuticals in the 3rd quarter worth about $263,000. 92.95% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: Understanding Market Liquidity

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.